%0 Journal Article
%T 艾司氯胺酮治疗难治性抑郁症研究新进展<br>New Progress in the Treatment of Refractory Depression with Esticketamine
%A 孙诗立
%A 范勇
%A 王春霞
%J Advances in Clinical Medicine
%P 4090-4095
%@ 2161-8720
%D 2022
%I Hans Publishing
%R 10.12677/ACM.2022.125592
%X 艾司氯胺酮作为一种新型抗抑郁药物，不同于传统抗抑郁药物的作用机制，主要通过拮抗N-甲基-D-天冬氨酸受体，激活α-氨基-3-羟基-5-甲基-4-异恶唑丙酸受体，增加脑源性神经营养因子(brain-derived neurotrophic factor, BDNF)及单胺类神经递质的释放，促进突触可再生等机制而发挥抗抑郁作用。服用艾司氯胺酮可快速缓解难治性抑郁症抑郁症状，迅速消除自杀意图，患者耐受性良好。本文就艾司氯胺酮治疗难治性抑郁症的作用机制及疗效做一综述。<br />
Asketamine, as a new antidepressant, is different from traditional antidepressants in its mecha-nism of action, mainly through antagonizing n-methyl-D-aspartic acid receptor, activating α-amino- 3-hydroxy-5-methyl-4-isooxazolpropionic acid receptor. It increases the release of brain-derived neurotrophic factor (BDNF) and monoamine neurotransmitter, promotes synaptic regeneration and other mechanisms to exert antidepressant effects. The administration of esketamine can quickly relieve the depressive symptoms of refractory depression and quickly eliminate the suicidal inten-tion, which is well tolerated by patients. This article reviews the mechanism and efficacy of esketa-mine in the treatment of refractory depression.
%K 艾司氯胺酮，难治性抑郁症，NMDA，BDNF<br>Esticketamine
%K Treatment-Resistant Depression
%K NMDA
%K BDNF
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=51351